This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a comparison of the efficacy of pegvisomant versus Sandostatin LAR in the treatment of patients with active acromegaly. The primary endpoint is to determine the percentage of patients in each group who achieve a normal serum IGF-1 concentration. Secondary endpoints are to compare the efficacy of pegvisomant with that of Sandostatin LAR on additional clinical and biochemical measures. This is a multicenter, open-label, parallel group, randomized dose optimization study.
Showing the most recent 10 out of 674 publications